A clinical formulation indicated for Diabetes. Combination therapy assists in the reduction of serum glucose concentration to promote better glycemic control.
Indicated to address high blood sugar by targeting glucose excretion and insulin regulation to alleviate metabolic strain and support cardiovascular health in adults.
Mechanism of Action
Linagliptin increases incretin hormones to boost insulin and lower liver sugar. Empagliflozin forces the kidneys to filter excess sugar out of the blood into the urine. This dual action provides comprehensive glucose control.
Route of Administration
Oral
Onset Time
Steady state in 2–5 days
Duration
24 hours
Contraindications
Severe kidney impairment, Dialysis, Diabetic ketoacidosis, Hypersensitivity
Severe Adverse Events
Acute pancreatitis, Diabetic ketoacidosis, Fournier's gangrene, Severe kidney injury, Heart failure risk, Severe joint pain
Information for Glyxambi is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
